SHARE

Dr. Lal Path Labs reports strong Q1 with profit growth and margin expansion

Indian diagnostics leader Dr. Lal Path Labs saw Q1 net profit rise 28% year-on-year to ₹169.5 crore on 19% revenue growth. EBITDA margin improved to 31%. Management raised FY27 revenue growth guidance to mid-teens, citing robust volume gains.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.